Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from TherapeuticsMD ( (TXMD) ).
On March 30, 2026, TherapeuticsMD reported full-year 2025 results, showing net loss from continuing operations narrowed to $0.7 million, or $0.06 per share, from $2.3 million, or $0.20 per share, in 2024. License revenue, mainly from its Mayne agreement, rose 71.6% to $3.0 million, operating expenses fell 5.9% to $7.4 million due to lower impairments, and the company ended 2025 with $7.5 million in cash.
The company said it is continuing to evaluate strategic alternatives, including potential M&A or asset sale transactions, but gave no timetable and cautioned there is no assurance a deal will occur. The improved loss profile, growing royalty revenue base and solid cash position underscore its transition to an asset-light royalty model while leaving open the prospect of a transformative corporate transaction for shareholders.
The most recent analyst rating on (TXMD) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on TherapeuticsMD stock, see the TXMD Stock Forecast page.
Spark’s Take on TXMD Stock
According to Spark, TipRanks’ AI Analyst, TXMD is a Neutral.
The score is driven primarily by improving financial performance (turn to positive net income and positive free cash flow) but held back by still-weak operating profitability. Technicals are supportive (price above key moving averages, positive MACD) yet show overbought conditions, while valuation is a key drag due to a very high P/E and no dividend support. Corporate updates are generally constructive but not decisive on their own.
To see Spark’s full report on TXMD stock, click here.
More about TherapeuticsMD
TherapeuticsMD, Inc., based in Boca Raton, Fla., is a Nasdaq-listed pharmaceutical royalty company that primarily collects royalties from licensees on women’s health products. The business, which ceased research, development and commercial operations after 2022, previously focused on innovative therapies spanning pregnancy prevention through menopause.
Average Trading Volume: 77,556
Technical Sentiment Signal: Hold
Current Market Cap: $24.31M
See more insights into TXMD stock on TipRanks’ Stock Analysis page.